Although the combination was deemed active in HR-positive, HER2-negative disease, findings don’t support further research.
Combining neoadjuvant pembrolizumab with radiotherapy prior to standard of care chemotherapy may increase pathologic complete responses rates in TNBC.
The majority of responses seen were ongoing at data cutoff.
The oncolytic virus pelareorep may mediate priming of an adaptive immune response in women with early breast cancer.
Improvements likely due to underlying genomic instability, increased sensitivity to DNA-damaging chemotherapy.
Women with lung, liver metastases and high PD-L1 expression saw a survival benefit.